The FDA has greenlit a European company’s AI software package designed to streamline workflow for radiologists reading prostate MRIs.

Google Health all but invited the blowback when its AI developer-researchers suggested their breast-cancer model may be superior to radiologists’ eyes and generalizable across differing demographics.

With their broad reach across all demographic categories, social media platforms are connecting healthcare influencers and stakeholders across every area of activity in which one might hold a stake. Of course, that’s a good thing and a bad thing.

Several large hospital systems in Southern California appear to have been dodging their duties to uninsured COVID patients.

The largest pharmacy chain in the U.S. is staffing up for fall and winter. It’s also calling for regulation that would allow pharmacy technicians to administer vaccinations in all states.  

If big data is to fulfill its potential for advancing the state of modern healthcare, developers of medical AI must be willing to show their work. 

Low-back imaging and interventions are often named among healthcare’s iffiest expenses due to the hit-or-miss predictability of the outcomes.

Weekly visits to some specialty practices have bounced back from the COVID swoon and then some. For many of these winners, in-person care is coming back to life right alongside telehealth.

Hawaii is the state with the best overall access to healthcare, achieving high scores for percentages of residents with a personal physician and children with a medical home while minimizing unmet needs for mental healthcare and doctor avoidance due to cost.

Of 125 public comments submitted to the FDA on how best to regulate AI software as a medical device, nearly two-thirds came from parties with financial ties to industry, according to a study running in BMJ Open.